Artificial intelligence in healthcare

ROHIT GORAI

Email: [rohitgorais143@gmail.com](mailto:rohitgorais143@gmail.com)

University Institute of Computing, Chandigarh University

October 24, 2025

**Abstract:** Artificial Intelligence (AI) is transforming healthcare with improved diagnostic precision, optimized clinical workflows, and personalized therapy. This paper integrates current research to examine AI's revolutionary uses in drug discovery, clinical trials, patient management, and health monitoring. AI speeds up drug development through automated target discovery and repurposing of known molecules, while in clinical trials, it facilitates improved recruitment of patients, lessens screening time, and increases accuracy of data. In healthcare, AI-powered devices e.g., robots, genetic testing, and intelligent diagnostics offer customized treatments and enhance patient outcomes. Monitoring systems use AI to anticipate risk, facilitate remote treatment, and minimize hospitalization.

Though promising, AI adoption is hindered by challenges that encompass data fragmentation, algorithmic bias, regulatory hurdles, and workforce preparedness. These can be met through solid data infrastructure, ethical frameworks, and collaborative governance. This paper recommends scalable AI integration with a focus on transparency, interoperability, and equal access to ensure AI benefits are delivered across healthcare systems.

**Keywords:** Artificial Intelligence, Healthcare, Drug Discovery, Clinical Trials, Patient Care, Health Monitoring, Ethical AI, Data Infrastructure

**Introduction:** Artificial Intelligence (AI) is transforming healthcare by enhancing diagnosis, automating clinical processes, and allowing for personalized patient treatment. As healthcare systems globally grapple with increasing costs, staff shortages, and more complex patients, AI provides innovative solutions to drive efficiency and effectiveness. AI utilizes enormous datasets such as electronic health records (EHRs), medical images, and real-time tracking to detect patterns and create actionable insights. In drug discovery, AI speeds up the process by automating target identification and repurposing already available drugs with huge cost and time savings. Firms such as Pfizer and Roche are already employing AI to accelerate cancer and metabolic disease treatments. In clinical trials, AI enhances patient recruitment and data accuracy, reducing screening time from months to minutes. Sites such as Mendel.ai have boosted trial enrollment by as much as 50%, improving efficiency and reliability. For healthcare, AI-based technologies such as virtual nurse assistants and intelligent prosthetics deliver customized care, minimizing hospital stays and enhancing autonomy. AI-based health monitoring systems anticipate the risks of heart failure, allowing for early treatment and improved outcomes. However, AI adoption faces challenges, including data fragmentation, algorithmic bias, regulatory hurdles, and workforce readiness. Addressing these requires robust

data infrastructure, ethical guidelines, and collaboration among stakeholders. This paper explores AI’s transformative potential in healthcare, its challenges, and future directions, emphasizing the need for equitable and patient-centered solutions.

**Literature Review:** Artificial Intelligence (AI) is revolutionizing healthcare by speeding up drug discovery, enhancing clinical trials, driving patient care, and solving major healthcare problems. In drug discovery, AI streamlines target identification, drug repurposing, and laboratory activities, saving timelines and expenses by as much as 50%. In clinical trials, AI quickens patient recruitment, enhances data validity, and facilitates adaptive trial design, saving costs and dropout rates. In healthcare, AI-enabled applications like virtual nurse assistants, intelligent prosthetics, and remote monitoring improve diagnosis, tailor treatment, and diminish hospital visits. Even as adoption of AI gets a boost, it is hampered by challenges such as data fragmentation, bias in algorithms, regulatory challenges, workforce preparedness, and high cost of infrastructure. Resolving these demands standard data systems, ethics guidelines, strong regulations, and participation among stakeholders. With scalable platforms, ethical governance, and patient-centered design, AI can transform healthcare into a more efficient, equitable, and personalized system that improves patient outcomes globally.

# Applications of AI in Healthcare:

**AI in Drug Discovery:** AI speeds up drug discovery through target identification automation, off-target compounds analysis, and repurposing of drugs (Shaheen, 2021).

**AI in Clinical Trials:** AI supports data monitoring, manages extensive data, and enhances trial precision (Vaananen et al., 2021).

**AI in Patient Care:** AI interprets patient information to give personalized suggestions and enhance quality of life (Shaheen, 2021).

**AI in Health Monitoring:** AI-equipped monitors monitor patient vitals, analyze health risk, and facilitate early intervention (Vaananen et al., 2021).

**Requirement:** An artificial intelligence-enabled data monitoring system for clinical trials needs to be developed to improve accuracy, efficiency, and compliance while overcoming the weaknesses of traditional manual approaches. The system should ingest and validate data automatically from various sources, such as electronic health records (EHRs), wearable devices, laboratory systems, and patient-reported outcomes (PROs), with real-time synchronization and minimal latency. Standardization of data is essential, unless support for FHIR, OMOP, and CDISC formats is provided to allow interoperability with current CTMS and EDC solutions such as Medidata Rave or OpenClinica. The system should also have manual override capabilities for exceptions, with full audit trails to record all changes for compliance with regulations. To enhance data quality and anomaly detection, the system should use machine learning algorithms to mark outliers, such as unlikely vitals or duplicate registrations, and alert possible data fabrication or error. Automated queries must be raised for site personnel to correct differences, and dashboards must offer real-time feedback to data managers on data quality measures, including error rates. Predictive analytics are necessary for proactive monitoring, allowing the system to predict negative events (e.g., drug toxicity or non- compliance) and notify investigators about high-risk subjects. The system must also suggest protocol amendments, like dose adjustments, by interim data analysis.

**Information Gain:** Information Gain (IG) is a prominent machine learning and data science concept used extensively to minimize uncertainty and make better decisions. In clinical trial monitoring with AI, IG is applied to determine the most informative features for outcome prediction, anomaly detection, and trial efficiency enhancement. IG is defined as parent entropy (total uncertainty) minus child entropy (uncertainty after data splitting). High IG means that a feature has a major role to play in improving predictions to be more accurate and reliable.

Within clinical trials, IG is very useful for feature selection, allowing AI systems to prioritize influential variables like demographics, biomarkers, treatment response, and behavioral variables. For instance, if liver enzyme level has high IG for the prediction of drug toxicity, the model emphasizes this variable over less predictive variables such as height to enhance accuracy and avoid overfitting. IG applies to anomaly detection, enabling systems to detect unusual deviations in essential signs, such as abrupt increases in blood pressure, that can trigger adverse events or data entry mistakes.

In addition, IG facilitates patient stratification by clustering individuals sharing common risk profiles by genetic or clinical biomarkers, resulting in individualized treatment strategies. In adaptive trial designs, AI has the capability to refine protocols in real time by utilising IG calculations, targeting monitoring intensification on high-impact features to speed trial completion and lower costs.

The advantages of IG are enhanced predictive performance, operational effectiveness, cost savings, and increased regulatory compliance through clear, data-informed decisions. Yet there are challenges: IG relies on high-quality, clearly labeled data, and biased or missing data can lead to flawed conclusions. In addition, models utilizing IG need to be explainable to clinicians and regulators, commonly done with clear AI techniques such as decision trees or SHAP values.

Practical application includes data preprocessing, calculation of IG through methods such as ID3 or Random Forests, model building, independent dataset validation, and ongoing monitoring. An oncology trial in actual practice proved IG's worth: tumor marker elevation and white blood cell count with high IG facilitated the AI system's ability to forecast treatment outcome at 90% accuracy, decreasing hospitalization by 30% and speeding completion.

**Conclusion:** Artificial Intelligence is transforming the healthcare industry by pushing the realms of efficiency, accuracy, and personalization in various areas such as drug discovery, clinical trials, patient care, and health tracking. Using machine learning methods such as Information Gain, AI systems can determine the most critical variables, which can make predictions more accurate and improve decision-making. In clinical trials, this results in better patient recruitment, quicker screening, real-time anomaly detection, and adaptive protocols, all decreasing cost and time. In patient care, AI-driven tools like smart diagnostics and monitoring systems allow early intervention, enhancing results and reducing hospital stays.

But unlocking the potential of AI needs to overcome some important challenges such as data fragmentation, algorithmic bias, regulatory hurdles, and workforce preparation. Provisioning for standard data infrastructures such as FHIR and CDISC formats promotes interoperability and compliance, while ethical frameworks and open governance promote trust and equity. In addition, predictive analytics and anomaly detection improve clinical trial data quality, enabling the early detection of risks and protocol refinement.

In general, AI provides a paradigmatic track toward transforming healthcare into a more efficient, fair, and patient-focused system. Its deployment in healthcare and clinical research needs to be well-planned, with a focus on transparency, explainability, and equal access. Through rigorous stakeholder collaboration, investment in strong data systems, and ethical guidance, AI-powered platforms are capable of transforming current healthcare delivery, driving innovation, and enhancing global patient outcomes. The future of medicine is in utilizing AI not only as a technological innovation but as an strategic ally in providing safer, swifter, and more efficient medical interventions.

# References:

1. N. Shaheen, “Artificial Intelligence in Drug Discovery and Development: Revolutionizing Pharmaceutical Innovation,” *J. Pharm. Innov.*, vol. 16, no. 4, pp. 389–401, 2021.
2. E. J. Topol, *Deep Medicine: How Artificial Intelligence Can Make Healthcare Human Again.* New York, NY, USA: Basic Books, 2019.
3. J. Väänänen, C. Berridge, and D. Cutler, “AI in Clinical Trials: Enhancing Patient Recruitment and Data Monitoring,” *Nat. Digit. Med.*, vol. 4, pp. 112–125, 2021.
4. Mendel.ai, “AI-Powered Clinical Trial Recruitment Platform,” *Mendel.ai*, 2023. [Online].

Available: https:/[/www.mendel.ai](http://www.mendel.ai/)

1. A. Esteva et al., “A guide to deep learning in healthcare,” *Nat. Med.*, vol. 25, no. 1, pp. 24– 29, 2019.
2. K. W. Johnson et al., “Artificial Intelligence in Cardiology,” *J. Am. Coll. Cardiol.*, vol. 71, no. 23, pp. 2668–2679, 2018.
3. World Health Organization, “Ethics and Governance of Artificial Intelligence for Health,”

*WHO*, Geneva, Switzerland, 2021.

1. Z. Obermeyer and E. J. Emanuel, “Predicting the future—Big data, machine learning, and

clinical medicine,” *N. Engl. J. Med.*, vol. 375, no. 13, pp. 1216–1219, 2016.

1. U.S. Food and Drug Administration (FDA), “Artificial Intelligence and Machine Learning in Drug Development,” 2022. [Online]. Available: https:/[/www.fda.gov](http://www.fda.gov/)
2. A. L. Beam and I. S. Kohane, “Big data and machine learning in health care,” *JAMA*, vol. 319, no. 13, pp. 1317–1318, 2018.